To the best of our knowledge, this is the first study to report that loss of CHD5 expression significantly correlates with unfavorable clinicopathological features of HCC patients, including tumor metastasis, recurrence, poor overall and tumor-free survival. This evidence concerns the gene CHD5 and hepatocellular carcinoma.